Spontaneous object recognition and its relevance to schizophrenia: a review of findings from pharmacological, genetic, lesion and developmental rodent models

RationaleSpontaneous (novel) object recognition (SOR) is one of the most widely used rodent behavioural tests. The opportunity for rapid data collection has made SOR a popular choice in studies that explore cognitive impairment in rodent models of schizophrenia, and that test the efficacy of drugs intended to reverse these deficits.ObjectivesWe provide an overview of the many recent studies that have used SOR to explore the mnemonic effects of manipulation of the key transmitter systems relevant to schizophrenia—the dopamine, glutamate, GABA, acetylcholine, serotonin and cannabinoid systems—alone or in combination. We also review the use of SOR in studying memory in genetically modified mouse models of schizophrenia, as well as in neurodevelopmental and lesion models. We end by discussing the construct and predictive validity, and translational relevance, of SOR with respect to cognitive impairment in schizophrenia.ResultsPerturbation of the dopamine or glutamate systems can generate robust and reliable impairment in SOR. Impaired performance is also seen following antagonism of the muscarinic acetylcholine system, or exposure to cannabinoid agonists. Cognitive enhancement has been reported using alpha7-nicotinic acetylcholine receptor agonists and 5-HT6 antagonists. Among non-pharmacological models, neonatal ventral hippocampal lesions and maternal immune activation can impair SOR, while mixed results have been obtained with mice carrying mutations in schizophrenia risk-associated genes, including neuregulin and COMT.ConclusionsWhile SOR is not without its limitations, the task represents a useful method for studying manipulations with relevance to cognitive impairment in schizophrenia, as well as the interactions between them.

[1]  Yuko Fujita,et al.  Phencyclidine-Induced Cognitive Deficits in Mice Are Improved by Subsequent Subchronic Administration of the Novel Selective α7 Nicotinic Receptor Agonist SSR180711 , 2008, Biological Psychiatry.

[2]  Serologic evidence of prenatal influenza in the etiology of schizophrenia , 2004 .

[3]  H. Lublin,et al.  Effects of Donepezil Adjunctive Treatment to Ziprasidone on Cognitive Deficits in Schizophrenia: A Double-blind, Placebo-Controlled Study , 2007, Clinical neuropharmacology.

[4]  T. Bussey,et al.  Hippocampal lesions that abolish spatial maze performance spare object recognition memory at delays of up to 48 hours , 2005, Hippocampus.

[5]  Sven Andréasson,et al.  CANNABIS AND SCHIZOPHRENIA A Longitudinal Study of Swedish Conscripts , 1987, The Lancet.

[6]  N. Pitsikas,et al.  The nitric oxide-releasing derivative of ferulic acid NCX 2057 antagonized delay-dependent and scopolamine-induced performance deficits in a recognition memory task in the rat , 2010, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[7]  J. Sweeney,et al.  Drug abuse in schizophrenic patients: clinical correlates and reasons for use. , 1991, The American journal of psychiatry.

[8]  G. Nomikos,et al.  Effects of Typical and Atypical Antipsychotics and Receptor Selective Compounds on Acetylcholine Efflux in the Hippocampus of the Rat , 2002, Neuropsychopharmacology.

[9]  T. Comery,et al.  Procognitive and Neuroprotective Activity of a Novel α7 Nicotinic Acetylcholine Receptor Agonist for Treatment of Neurodegenerative and Cognitive Disorders , 2009, Journal of Pharmacology and Experimental Therapeutics.

[10]  G. Robertson,et al.  Darbepoetin alfa (Aranesp®) improves recognition memory in adult rats that have sustained bilateral ventral hippocampal lesions as neonates or young adults , 2007, Neuroscience.

[11]  E. Godaux,et al.  GSK3ß, a centre-staged kinase in neuropsychiatric disorders, modulates long term memory by inhibitory phosphorylation at Serine-9 , 2009, Neurobiology of Disease.

[12]  G. Reynolds,et al.  Effect of pretreatment with risperidone on phencyclidine-induced disruptions in object recognition memory and prefrontal cortex parvalbumin immunoreactivity in the rat , 2010, Behavioural Brain Research.

[13]  M. Day,et al.  Correlating Efficacy in Rodent Cognition Models with in Vivo 5-Hydroxytryptamine1A Receptor Occupancy by a Novel Antagonist, (R)-N-(2-Methyl-(4-indolyl-1-piperazinyl)ethyl)-N-(2-pyridinyl)-cyclohexane Carboxamide (WAY-101405) , 2008, Journal of Pharmacology and Experimental Therapeutics.

[14]  P. Seeman,et al.  Antipsychotic drugs: direct correlation between clinical potency and presynaptic action on dopamine neurons. , 1975, Science.

[15]  Hughes,et al.  Correlating Efficacy in Rodent Cognition Models with In Vivo 5-HT 1 A Receptor Occupancy by a Novel Antagonist , 2008 .

[16]  A. Sleight,et al.  Reversal of a cholinergic-induced deficit in a rodent model of recognition memory by the selective 5-HT6 receptor antagonist, Ro 04-6790 , 2003, Psychopharmacology.

[17]  S. Katayama,et al.  Subsequent exposure to the choline uptake enhancer MKC-231 antagonizes phencyclidine-induced behavioral deficits and reduction in septal cholinergic neurons in rats , 2007, European Neuropsychopharmacology.

[18]  Karl J. Friston,et al.  The left medial temporal region and schizophrenia. A PET study. , 1992, Brain : a journal of neurology.

[19]  L. Rothblat,et al.  Short-term object recognition memory in the rat: nonmatching with trial-unique junk stimuli. , 1987, Behavioral neuroscience.

[20]  J. Vry,et al.  The Novel α7 Nicotinic Acetylcholine Receptor Agonist N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide Improves Working and Recognition Memory in Rodents , 2007, Journal of Pharmacology and Experimental Therapeutics.

[21]  E. Levin,et al.  Nicotinic-antipsychotic drug interactions and cognitive function. , 2006, EXS.

[22]  J C Gordon,et al.  The 5-HT3 antagonist tropisetron (ICS 205-930) is a potent and selective alpha7 nicotinic receptor partial agonist. , 2001, Bioorganic & medicinal chemistry letters.

[23]  R. Ebstein,et al.  Dopamine D4 receptor (D4DR) exon III polymorphism associated with the human personality trait of Novelty Seeking , 1996, Nature Genetics.

[24]  Herbert Y Meltzer,et al.  Efficacy and Safety of Donepezil in Patients with Schizophrenia or Schizoaffective Disorder: Significant Placebo/Practice Effects in a 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial , 2008, Neuropsychopharmacology.

[25]  Robert E. Clark,et al.  Impaired Recognition Memory in Rats after Damage to the Hippocampus , 2000, The Journal of Neuroscience.

[26]  Kevin B Baker,et al.  Effects of stress and hippocampal NMDA receptor antagonism on recognition memory in rats. , 2002, Learning & memory.

[27]  F. Lung,et al.  Association of DRD4 uVNTR and TP53 codon 72 polymorphisms with schizophrenia: a case-control study , 2009, BMC Medical Genetics.

[28]  C. Messier Object Recognition in Mice: Improvement of Memory by Glucose , 1997, Neurobiology of Learning and Memory.

[29]  R. Freedman,et al.  Proof-of-concept trial of an alpha7 nicotinic agonist in schizophrenia. , 2006, Archives of general psychiatry.

[30]  R. Gainetdinov,et al.  The Physiology, Signaling, and Pharmacology of Dopamine Receptors , 2011, Pharmacological Reviews.

[31]  J. Waddington,et al.  Chronic Adolescent Exposure to Δ-9-Tetrahydrocannabinol in COMT Mutant Mice: Impact on Psychosis-Related and Other Phenotypes , 2010, Neuropsychopharmacology.

[32]  N. Alpert,et al.  Abnormalities in the thalamus and prefrontal cortex during episodic object recognition in schizophrenia , 2000, Biological Psychiatry.

[33]  J. Glennon,et al.  SLV313 (1-(2,3-Dihydro-Benzo[1,4]Dioxin-5-yl)-4- [5-(4-Fluoro-Phenyl)-Pyridin-3-ylmethyl]-Piperazine Monohydrochloride): A Novel Dopamine D2 Receptor Antagonist and 5-HT1A Receptor Agonist Potential Antipsychotic Drug , 2007, Neuropsychopharmacology.

[34]  H. Meltzer,et al.  Effect of muscarinic receptor agonists xanomeline and sabcomeline on acetylcholine and dopamine efflux in the rat brain; comparison with effects of 4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one (AC260584) and N-desmethylclozapine. , 2008, European journal of pharmacology.

[35]  A. E. A. Yağcıoğlu,et al.  A double-blind, placebo controlled, cross-over trial of adjunctive donepezil for cognitive impairment in schizophrenia. , 2004, The international journal of neuropsychopharmacology.

[36]  Rosemary A. Cowell,et al.  Perceptual Functions of Perirhinal Cortex in Rats: Zero-Delay Object Recognition and Simultaneous Oddity Discriminations , 2007, The Journal of Neuroscience.

[37]  S. Totterdell,et al.  Enhanced anxiety, depressive‐like behaviour and impaired recognition memory in mice with reduced expression of the vesicular glutamate transporter 1 (VGLUT1) , 2007, The European journal of neuroscience.

[38]  R. Schreiber,et al.  The Selective 5-HT6 Receptor Antagonist Ro4368554 Restores Memory Performance in Cholinergic and Serotonergic Models of Memory Deficiency in the Rat , 2005, Neuropsychopharmacology.

[39]  Jared W. Young,et al.  Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. , 2009, Pharmacology & therapeutics.

[40]  L. Saksida,et al.  New translational assays for preclinical modelling of cognition in schizophrenia: The touchscreen testing method for mice and rats , 2012, Neuropharmacology.

[41]  Yuko Fujita,et al.  Phencyclidine-induced cognitive deficits in mice are ameliorated by subsequent subchronic administration of donepezil: Role of sigma-1 receptors , 2009, Brain Research.

[42]  Keith A. Young,et al.  Galantamine Improves Cognition in Schizophrenic Patients Stabilized on Risperidone , 2006, Biological Psychiatry.

[43]  B. Bogerts,et al.  Cellular changes in rat brain areas associated with neonatal hippocampal damage. , 1999, Neuroreport.

[44]  L R Squire,et al.  On the development of declarative memory. , 1993, Journal of experimental psychology. Learning, memory, and cognition.

[45]  Yuko Fujita,et al.  Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antibiotic drug minocycline , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[46]  F. Liu,et al.  ADX47273 [S-(4-Fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piperidin-1-yl}-methanone]: A Novel Metabotropic Glutamate Receptor 5-Selective Positive Allosteric Modulator with Preclinical Antipsychotic-Like and Procognitive Activities , 2008, Journal of Pharmacology and Experimental Therapeutics.

[47]  Michael F. Green,et al.  Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. , 2006, The Journal of clinical psychiatry.

[48]  R. Freedman,et al.  Effects of Nicotine on Cognitive Deficits in Schizophrenia , 2004, Neuropsychopharmacology.

[49]  W. Montfort,et al.  The nitric oxide-releasing heme proteins from the saliva of the blood-sucking insect Rhodnius prolixus , 2000 .

[50]  E. Wong,et al.  Asenapine Increases Dopamine, Norepinephrine, and Acetylcholine Efflux in the Rat Medial Prefrontal Cortex and Hippocampus , 2008, Neuropsychopharmacology.

[51]  Michael F. Green,et al.  Methamphetamine dependence is associated with neurocognitive impairment in the initial phases of abstinence. , 2003, The Journal of neuropsychiatry and clinical neurosciences.

[52]  R. Papke,et al.  TC-5619: an alpha7 neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia. , 2009, Biochemical pharmacology.

[53]  L. Dawson,et al.  Effects of 5-HT6 receptor blockade on the neurochemical outcome of antidepressant treatment in the frontal cortex of the rat , 2003, Journal of Neural Transmission.

[54]  Joseph P. Huston,et al.  The pharmacology, neuroanatomy and neurogenetics of one-trial object recognition in rodents , 2007, Neuroscience & Biobehavioral Reviews.

[55]  Bita Moghaddam,et al.  NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[56]  J. Crabbe,et al.  Genetics of mouse behavior: interactions with laboratory environment. , 1999, Science.

[57]  W. Scoville,et al.  LOSS OF RECENT MEMORY AFTER BILATERAL HIPPOCAMPAL LESIONS , 1957, Journal of neurology, neurosurgery, and psychiatry.

[58]  D. Rasmusson The role of acetylcholine in cortical synaptic plasticity , 2000, Behavioural Brain Research.

[59]  J. Neill,et al.  Activation of α7 nicotinic receptors improves phencyclidine-induced deficits in cognitive tasks in rats: Implications for therapy of cognitive dysfunction in schizophrenia , 2011, European Neuropsychopharmacology.

[60]  Alan S. Brown,et al.  Prenatal infection as a risk factor for schizophrenia. , 2006, Schizophrenia bulletin.

[61]  Thomas J. Raub,et al.  Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationship. , 2006, Journal of medicinal chemistry.

[62]  A. Sawa,et al.  Combined effect of neonatal immune activation and mutant DISC1 on phenotypic changes in adulthood , 2010, Behavioural Brain Research.

[63]  A. Carlsson,et al.  EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN. , 2009, Acta pharmacologica et toxicologica.

[64]  T. Robbins Synthesizing schizophrenia: a bottom-up, symptomatic approach. , 2005, Schizophrenia bulletin.

[65]  O. Pascalis,et al.  Visual paired comparison performance is impaired in a patient with selective hippocampal lesions and relatively intact item recognition , 2004, Neuropsychologia.

[66]  T. Bussey,et al.  Functionally Dissociating Aspects of Event Memory: the Effects of Combined Perirhinal and Postrhinal Cortex Lesions on Object and Place Memory in the Rat , 1999, The Journal of Neuroscience.

[67]  T. Comery,et al.  5-Cyclic amine-3-arylsulfonylindazoles as novel 5-HT6 receptor antagonists. , 2010, Journal of Medicinal Chemistry.

[68]  R. Roesler,et al.  Pre- or post-training administration of the NMDA receptor blocker MK-801 impairs object recognition memory in rats , 2005, Behavioural Brain Research.

[69]  R. Quirion,et al.  Local modulation of hippocampal acetylcholine release by dopamine D1 receptors: a combined receptor autoradiography and in vivo dialysis study , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[70]  James M Gold,et al.  Galantamine for the treatment of cognitive impairments in people with schizophrenia. , 2008, The American journal of psychiatry.

[71]  D. Weinberger,et al.  Genetic Dissection of the Role of Catechol-O-Methyltransferase in Cognition and Stress Reactivity in Mice , 2008, The Journal of Neuroscience.

[72]  A. Malhotra,et al.  Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia. , 1999, The American journal of psychiatry.

[73]  Sarah L. Huszar,et al.  The Behavioral and Neurochemical Effects of a Novel d-Amino Acid Oxidase Inhibitor Compound 8 [4H-Thieno [3,2-b]pyrrole-5-carboxylic Acid] and d-Serine , 2008, Journal of Pharmacology and Experimental Therapeutics.

[74]  V. R. Marcy,et al.  Activation of the 5-HT6 receptor attenuates long-term potentiation and facilitates GABAergic neurotransmission in rat hippocampus , 2009, Neuroscience.

[75]  Rosemary A. Cowell,et al.  Why Does Brain Damage Impair Memory? A Connectionist Model of Object Recognition Memory in Perirhinal Cortex , 2006, The Journal of Neuroscience.

[76]  A. Yonelinas,et al.  Recollection and familiarity: Examining controversial assumptions and new directions , 2010, Hippocampus.

[77]  S. Lal,et al.  Nicotine and Behavioral Markers of Risk for Schizophrenia: A Double-Blind, Placebo-Controlled, Cross-Over Study , 2002, Neuropsychopharmacology.

[78]  L. Dawson,et al.  The 5-HT6 Receptor Antagonist SB-271046 Selectively Enhances Excitatory Neurotransmission in the Rat Frontal Cortex and Hippocampus , 2001, Neuropsychopharmacology.

[79]  J. Neumaier,et al.  5-HT6 receptors: a novel target for cognitive enhancement. , 2005, Pharmacology & therapeutics.

[80]  T. Rodrigo,et al.  Memantine is a useful drug to prevent the spatial and non-spatial memory deficits induced by methamphetamine in rats. , 2010, Pharmacological research.

[81]  P. Goldman-Rakic Working memory dysfunction in schizophrenia. , 1994, The Journal of neuropsychiatry and clinical neurosciences.

[82]  Sophia Vinogradov,et al.  Association of anticholinergic load with impairment of complex attention and memory in schizophrenia. , 2004, The American journal of psychiatry.

[83]  P. Allebeck,et al.  CANNABIS AND SCHIZOPHRENIA , 1988, The Lancet.

[84]  E. Wood,et al.  Nonrecurring-items delayed nonmatching-to-sample in rats: A new paradigm for testing nonspatial working memory , 1990, Psychobiology.

[85]  T. Wienker,et al.  Splitting schizophrenia: periodic catatonia-susceptibility locus on chromosome 15q15. , 2000, American journal of human genetics.

[86]  H. Meltzer,et al.  Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism , 2002, Brain Research.

[87]  T. Abel,et al.  Neuregulin 1 transgenic mice display reduced mismatch negativity, contextual fear conditioning and social interactions , 2009, Brain Research.

[88]  Z. Bashir,et al.  A temporally distinct role for group I and group II metabotropic glutamate receptors in object recognition memory. , 2006, Learning & memory.

[89]  T. Svensson,et al.  Asenapine elevates cortical dopamine, noradrenaline and serotonin release. Evidence for activation of cortical and subcortical dopamine systems by different mechanisms , 2009, Psychopharmacology.

[90]  J. Haller,et al.  WIN-55,212-2 chronically implanted into the CA3 region of the dorsal hippocampus impairs learning: a novel method for studying chronic, brain-area-specific effects of cannabinoids , 2007, Behavioural pharmacology.

[91]  Robert Freedman,et al.  Proof-of-Concept Trial of an α7 Nicotinic Agonist in Schizophrenia , 2006 .

[92]  John P. Aggleton,et al.  Interleaving brain systems for episodic and recognition memory , 2006, Trends in Cognitive Sciences.

[93]  P. Patterson,et al.  Maternal immune activation alters nonspatial information processing in the hippocampus of the adult offspring , 2010, Brain, Behavior, and Immunity.

[94]  M. W. Brown,et al.  Evidence concerning how neurons of the perirhinal cortex may effect familiarity discrimination. , 2002, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[95]  Boyer D. Winters,et al.  Object recognition memory: Neurobiological mechanisms of encoding, consolidation and retrieval , 2008, Neuroscience & Biobehavioral Reviews.

[96]  L. Dawson,et al.  In vivo effects of the 5‐HT6 antagonist SB‐271046 on striatal and frontal cortex extracellular concentrations of noradrenaline, dopamine, 5‐HT, glutamate and aspartate , 2000, British journal of pharmacology.

[97]  C L DeVane,et al.  A Double-blind Placebo-controlled Case Study of the Use of Donepezil to Improve Cognition in a Schizoaffective Disorder Patient: Functional MRI Correlates. , 2001, Neurocase.

[98]  A. Phillips,et al.  Medial prefrontal cortex is involved in spatial temporal order memory but not spatial recognition memory in tests relying on spontaneous exploration in rats , 2004, Behavioural Brain Research.

[99]  L. Dawson,et al.  The 5-HT(6) receptor antagonist SB-271046 selectively enhances excitatory neurotransmission in the rat frontal cortex and hippocampus. , 2001, Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology.

[100]  Raquel E Gur,et al.  Face recognition memory deficits and visual object memory performance in patients with schizophrenia and their relatives. , 2005, The American journal of psychiatry.

[101]  D. Suchecki,et al.  Pituitary-adrenal and interleukin-6 responses to recombinant interleukin-1 in neonatal rats , 1994, Psychoneuroendocrinology.

[102]  S. Lal,et al.  Cognitive and clinical moderators of recognition memory in schizophrenia: a meta-analysis , 2005, Schizophrenia Research.

[103]  Jill Harkavy-Friedman,et al.  Resting neural activity distinguishes subgroups of schizophrenia patients , 2004, Biological Psychiatry.

[104]  S. Bate,et al.  Selective dopamine D4 receptor agonist (A-412997) improves cognitive performance and stimulates motor activity without influencing reward-related behaviour in rat , 2008, Behavioural pharmacology.

[105]  T. Bussey,et al.  Distinct patterns of behavioural impairments resulting from fornix transection or neurotoxic lesions of the perirhinal and postrhinal cortices in the rat , 2000, Behavioural Brain Research.

[106]  Ralph Lydic,et al.  Adenosine A1 and A2A Receptors in Mouse Prefrontal Cortex Modulate Acetylcholine Release and Behavioral Arousal , 2009, The Journal of Neuroscience.

[107]  Gary Remington,et al.  Dopamine D2 receptors and their role in atypical antipsychotic action: still necessary and may even be sufficient , 2001, Biological Psychiatry.

[108]  Malcolm W. Brown,et al.  Cholinergic Neurotransmission Is Essential for Perirhinal Cortical Plasticity and Recognition Memory , 2003, Neuron.

[109]  P. Celada,et al.  Involvement of 5-HT1A Receptors in Prefrontal Cortex in the Modulation of Dopaminergic Activity: Role in Atypical Antipsychotic Action , 2005, The Journal of Neuroscience.

[110]  Pedro Grandes,et al.  Dopaminergic Modulation of Endocannabinoid-Mediated Plasticity at GABAergic Synapses in the Prefrontal Cortex , 2010, The Journal of Neuroscience.

[111]  G. Griebel,et al.  SSR180711, a Novel Selective α7 Nicotinic Receptor Partial Agonist: (II) Efficacy in Experimental Models Predictive of Activity Against Cognitive Symptoms of Schizophrenia , 2007, Neuropsychopharmacology.

[112]  T. Nabeshima,et al.  Repeated methamphetamine treatment impairs spatial working memory in rats: reversal by clozapine but not haloperidol , 2007, Psychopharmacology.

[113]  P. Allebeck,et al.  Signs of asphyxia at birth and risk of schizophrenia , 2001, British Journal of Psychiatry.

[114]  J. Lieberman,et al.  A Randomized, Placebo-Controlled Study of Memantine as Adjunctive Treatment in Patients with Schizophrenia , 2009, Neuropsychopharmacology.

[115]  E. Levin,et al.  Nicotinic acetylcholine involvement in cognitive function in animals , 1998, Psychopharmacology.

[116]  Michael Koch,et al.  Chronic Pubertal, but not Adult Chronic Cannabinoid Treatment Impairs Sensorimotor Gating, Recognition Memory, and the Performance in a Progressive Ratio Task in Adult Rats , 2003, Neuropsychopharmacology.

[117]  D. Greenblatt,et al.  Withdrawal reaction from long-term, low-dosage administration of diazepam. A double-blind, placebo-controlled case study. , 1980, Archives of general psychiatry.

[118]  M. Miguéns,et al.  Chronic periadolescent cannabinoid treatment enhances adult hippocampal PSA-NCAM expression in male Wistar rats but only has marginal effects on anxiety, learning and memory , 2009, Pharmacology Biochemistry and Behavior.

[119]  Martín Cammarota,et al.  Posttraining activation of CB1 cannabinoid receptors in the CA1 region of the dorsal hippocampus impairs object recognition long-term memory , 2008, Neurobiology of Learning and Memory.

[120]  David R. Thomas,et al.  Role of 5-HT receptor mechanisms in sub-chronic PCP-induced reversal learning deficits in the rat , 2009, Psychopharmacology.

[121]  M. Tsuang,et al.  Brief Research Communication Linkage Disequilibrium for Schizophrenia at the Chromosome 15q13-14 Locus of the a7-Nicotinic Acetylcholine Receptor Subunit Gene (CHRNA7) , 2001 .

[122]  J. Aggleton,et al.  Neurotoxic lesions of the perirhinal cortex do not mimic the behavioural effects of fornix transection in the rat , 1996, Behavioural Brain Research.

[123]  D. Bertrand,et al.  RG3487, a Novel Nicotinic α7 Receptor Partial Agonist, Improves Cognition and Sensorimotor Gating in Rodents , 2011, Journal of Pharmacology and Experimental Therapeutics.

[124]  Maryam Noroozian,et al.  A 12-week, double-blind, placebo-controlled trial of donepezil adjunctive treatment to risperidone in chronic and stable schizophrenia , 2008, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[125]  D. Goff,et al.  Added donepezil for stable schizophrenia: a double-blind, placebo-controlled trial , 2005, Psychopharmacology.

[126]  M. W. Brown,et al.  Recognition memory: neuronal substrates of the judgement of prior occurrence , 1998, Progress in Neurobiology.

[127]  M. Egan,et al.  Catechol O-methyltransferase val158-met genotype and individual variation in the brain response to amphetamine , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[128]  H. Eichenbaum,et al.  Serine racemase deletion disrupts memory for order and alters cortical dendritic morphology , 2011, Genes, brain, and behavior.

[129]  E. Bromley A collaborative approach to targeted treatment development for schizophrenia: a qualitative evaluation of the NIMH-MATRICS project. , 2005, Schizophrenia bulletin.

[130]  J. Frahm,et al.  Complexin2 null mutation requires a ‘second hit’ for induction of phenotypic changes relevant to schizophrenia , 2010, Genes, brain, and behavior.

[131]  T. Nabeshima,et al.  Repeated Methamphetamine Treatment Impairs Recognition Memory Through a Failure of Novelty-Induced ERK1/2 Activation in the Prefrontal Cortex of Mice , 2006, Biological Psychiatry.

[132]  G. Reynolds,et al.  A selective reduction in the relative density of parvalbumin-immunoreactive neurons in the hippocampus in schizophrenia patients. , 2002, Chinese medical journal.

[133]  Matthew P. Schroeder,et al.  Nicotine enhances but does not normalize visual sustained attention and the associated brain network in schizophrenia. , 2011, Schizophrenia bulletin.

[134]  Z. Bashir,et al.  Activation of muscarinic receptors induces protein synthesis‐dependent long‐lasting depression in the perirhinal cortex , 2001, The European journal of neuroscience.

[135]  T. Woo,et al.  Schizophrenia and the parvalbumin-containing class of cortical local circuit neurons. , 1997, The American journal of psychiatry.

[136]  A. Sahgal,et al.  The role of serotonergic-cholinergic interactions in the mediation of cognitive behaviour , 1995, Behavioural Brain Research.

[137]  Yuko Fujita,et al.  Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of clozapine, but not haloperidol. , 2005, European journal of pharmacology.

[138]  B. Moghaddam,et al.  Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. , 1998, Science.

[139]  D. Lewis,et al.  Cortical inhibitory neurons and schizophrenia , 2005, Nature Reviews Neuroscience.

[140]  R. Schreiber,et al.  Effects of the novel 5-HT 6 receptor antagonist RO4368554 in rat models for cognition and , 2007 .

[141]  J. Schneider,et al.  The dopamine D3 receptor antagonist, S33138, counters cognitive impairment in a range of rodent and primate procedures. , 2010, The international journal of neuropsychopharmacology.

[142]  T. Karl,et al.  Cognition in transmembrane domain neuregulin 1 mutant mice , 2010, Neuroscience.

[143]  Mary Johnson,et al.  Laminar distribution of nicotinic receptor subtypes in cortical regions in schizophrenia , 2001, Journal of Chemical Neuroanatomy.

[144]  P. Coyle,et al.  Maternal dietary zinc supplementation prevents aberrant behaviour in an object recognition task in mice offspring exposed to LPS in early pregnancy , 2009, Behavioural Brain Research.

[145]  K. Davis,et al.  Dopamine in schizophrenia: a review and reconceptualization. , 1991, The American journal of psychiatry.

[146]  Sylvain Williams,et al.  Behavioral characterization of dysbindin-1 deficient sandy mice , 2009, Behavioural Brain Research.

[147]  Peter B. Jones,et al.  Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review , 2007, The Lancet.

[148]  T. Nabeshima,et al.  Galantamine ameliorates the impairment of recognition memory in mice repeatedly treated with methamphetamine: involvement of allosteric potentiation of nicotinic acetylcholine receptors and dopaminergic-ERK1/2 systems. , 2010, The international journal of neuropsychopharmacology.

[149]  Abraham Weizman,et al.  Addition of memantine to antipsychotic treatment in schizophrenia inpatients with residual symptoms: A preliminary study , 2008, European Neuropsychopharmacology.

[150]  R. Freedman,et al.  Genetic linkage to schizophrenia at chromosome 15q14. , 2001, American journal of medical genetics.

[151]  Michael A. Dyer,et al.  High-dose galantamine augmentation inferior to placebo on attention, inhibitory control and working memory performance in nonsmokers with schizophrenia , 2008, Schizophrenia Research.

[152]  Daniel R. Weinberger,et al.  Neonatal lesions of the rat ventral hippocampus result in hyperlocomotion and deficits in social behaviour in adulthood , 1997, Psychopharmacology.

[153]  Nicholas Lange,et al.  D-serine added to antipsychotics for the treatment of schizophrenia , 1998, Biological Psychiatry.

[154]  C. Vorhees,et al.  Effect of (+)-methamphetamine on path integration learning, novel object recognition, and neurotoxicity in rats , 2008, Psychopharmacology.

[155]  B. Grayson,et al.  Atypical antipsychotics attenuate a sub-chronic PCP-induced cognitive deficit in the novel object recognition task in the rat , 2007, Behavioural Brain Research.

[156]  S. Faraone,et al.  Organizational and Visual Memory Deficits in Schizophrenia and Bipolar Psychoses Using the Rey-Osterrieth Complex Figure: Effects of Duration of Illness , 2003, Journal of clinical and experimental neuropsychology.

[157]  M. Chan,et al.  Attenuation of ketamine-evoked behavioral responses by mGluR5 positive modulators in mice , 2008, Psychopharmacology.

[158]  T. Nabeshima,et al.  Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D1 and serotonin 5-HT1A receptors , 2008, Psychopharmacology.

[159]  A. Carlsson,et al.  Differential effects of the N-methyl-d-aspartate receptor antagonist MK-801 on different stages of object recognition memory in mice , 2007, Neuroscience.

[160]  Alexander Easton,et al.  Recollection in an episodic-like memory task in the rat. , 2005, Learning & memory.

[161]  D. Mathalon,et al.  The contribution of constructional accuracy and organizational strategy to nonverbal recall in Schizophrenia and chronic alcoholism , 1992, Biological Psychiatry.

[162]  J. A. Dani,et al.  Nicotinic Stimulation Produces Multiple Forms of Increased Glutamatergic Synaptic Transmission , 1998, The Journal of Neuroscience.

[163]  Yue-Cune Chang,et al.  A randomized, double-blind, placebo-controlled comparison study of sarcosine (N-methylglycine) and D-serine add-on treatment for schizophrenia. , 2010, The international journal of neuropsychopharmacology.

[164]  陳柏維,et al.  Glycine Transporter I Inhibitor, N-methylglycine (Sarcosine), Added to Clozapine for the Treatment of Schizophrenia , 2005 .

[165]  Philip D. Harvey,et al.  A double blind placebo controlled trial of donepezil adjunctive treatment to risperidone for the cognitive impairment of schizophrenia , 2002, Biological Psychiatry.

[166]  J. Coyle,et al.  Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis , 2006, Cellular and Molecular Neurobiology.

[167]  D. Bowen,et al.  NMDA‐induced glutamate and aspartate release from rat cortical pyramidal neurones: evidence for modulation by a 5‐HT1A antagonist , 1995, British journal of pharmacology.

[168]  C. Regan,et al.  SB-399885 is a potent, selective 5-HT6 receptor antagonist with cognitive enhancing properties in aged rat water maze and novel object recognition models. , 2006, European journal of pharmacology.

[169]  T. Bussey,et al.  Extensive Cytotoxic Lesions Involving Both the Rhinal Cortices and Area TE Impair Recognition But Spare Spatial Alternation in the Rat , 1997, Brain Research Bulletin.

[170]  J. Leon,et al.  A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors , 2005, Schizophrenia Research.

[171]  T. Abel,et al.  Deficits in spatial memory correlate with modified γ-aminobutyric acid type A receptor tyrosine phosphorylation in the hippocampus , 2009, Proceedings of the National Academy of Sciences.

[172]  B. Pitt Psychopharmacology , 1968, Mental Health.

[173]  P. Mortensen,et al.  Obstetric conditions and risk of first admission with schizophrenia: A Danish national register based study , 2007, Schizophrenia Research.

[174]  D. Javitt Sensory processing in schizophrenia: neither simple nor intact. , 2009, Schizophrenia bulletin.

[175]  G. Thaker,et al.  Nicotine improves delayed recognition in schizophrenic patients , 2004, Psychopharmacology.

[176]  Paul W Smith,et al.  The discovery of a series of N-substituted 3-(4-piperidinyl)-1,3-benzoxazolinones and oxindoles as highly brain penetrant, selective muscarinic M1 agonists. , 2010, Bioorganic & medicinal chemistry letters.

[177]  Sara B. Taylor,et al.  Sex-specific neuroendocrine and behavioral phenotypes in hypomorphic Type II Neuregulin 1 rats , 2011, Behavioural Brain Research.

[178]  P. Gebicke-haerter,et al.  Nicotinamide prevents the long-term effects of perinatal asphyxia on apoptosis, non-spatial working memory and anxiety in rats , 2010, Experimental Brain Research.

[179]  J. Waddington,et al.  Phenotypic characterization of cognition and social behavior in mice with heterozygous versus homozygous deletion of catechol-O-methyltransferase , 2008, Neuroscience.

[180]  A. Lajtha,et al.  Cognitive and antismoking effects of varenicline in patients with schizophrenia or schizoaffective disorder , 2009, Schizophrenia Research.

[181]  Robert C. Smith,et al.  Effects of Nicotine Nasal Spray on Cognitive Function in Schizophrenia , 2006, Neuropsychopharmacology.

[182]  J. Uslaner,et al.  Dose-dependent effect of CDPPB, the mGluR5 positive allosteric modulator, on recognition memory is associated with GluR1 and CREB phosphorylation in the prefrontal cortex and hippocampus , 2009, Neuropharmacology.

[183]  S. Mosolov,et al.  Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial , 2007, Nature Medicine.

[184]  L. Saksida,et al.  Muscimol, AP5, or scopolamine infused into perirhinal cortex impairs two-choice visual discrimination learning in rats , 2010, Neurobiology of Learning and Memory.

[185]  D. Gaffan,et al.  Recognition impaired and association intact in the memory of monkeys after transection of the fornix. , 1974, Journal of comparative and physiological psychology.

[186]  M. Carli,et al.  WAY 100635, a 5-HT1A receptor antagonist, prevents the impairment of spatial learning caused by intrahippocampal administration of scopolamine or 7-chloro-kynurenic acid , 1997, Brain Research.

[187]  S. O'dell,et al.  Neurotoxic methamphetamine regimen severely impairs recognition memory in rats , 2003, Synapse.

[188]  M. Millan,et al.  S33138 [N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1]-benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenylacetamide], A Preferential Dopamine D3 versus D2 Receptor Antagonist and Potential Antipsychotic Agent: I. Receptor-Binding Profile and Functional Actions at G-Protein-Coupled Receptors , 2008, Journal of Pharmacology and Experimental Therapeutics.

[189]  J. Bachevalier,et al.  The Hippocampal/Parahippocampal Regions and Recognition Memory: Insights from Visual Paired Comparison versus Object-Delayed Nonmatching in Monkeys , 2004, The Journal of Neuroscience.

[190]  John J. Foxe,et al.  Impaired visual object recognition and dorsal/ventral stream interaction in schizophrenia. , 2002, Archives of general psychiatry.

[191]  Hiroshi Abe,et al.  Perirhinal N-methyl-d-aspartate and muscarinic systems participate in object recognition in rats , 2004, Neuroscience Letters.

[192]  Young Hoon Kim,et al.  A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia , 2007, International clinical psychopharmacology.

[193]  N. Kanahara,et al.  A randomised, double-blind, placebo-controlled trial of tropisetron in patients with schizophrenia , 2010, Annals of general psychiatry.

[194]  G. Higgins,et al.  Effect of scopolamine on visual attention in rats , 1995, Psychopharmacology.

[195]  Paul J. Harrison,et al.  Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence , 2005, Molecular Psychiatry.

[196]  P. Sullivan,et al.  Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. , 2003, Archives of general psychiatry.

[197]  Jian Fei,et al.  Cognitive impairment in mice over-expressing &ggr;-aminobutyric acid transporter I (GAT1) , 2004, Neuroreport.

[198]  H. Moore,et al.  Trans-Synaptic Stimulation of Cortical Acetylcholine Release after Partial 192 IgG-Saporin-Induced Loss of Cortical Cholinergic Afferents , 1996, The Journal of Neuroscience.

[199]  T. Rammsayer,et al.  Effects of pharmacologically induced changes in NMDA-receptor activity on long-term memory in humans. , 2001, Learning & memory.

[200]  F. Bymaster,et al.  Towards a muscarinic hypothesis of schizophrenia , 2007, Molecular Psychiatry.

[201]  R. Chesworth,et al.  A follow-up study: acute behavioural effects of Δ9-THC in female heterozygous Neuregulin 1 transmembrane domain mutant mice , 2010, Psychopharmacology.

[202]  Xuechu Zhen,et al.  Evaluation of the antipsychotic effect of bi-acetylated l-stepholidine (l-SPD-A), a novel dopamine and serotonin receptor dual ligand , 2009, Schizophrenia Research.

[203]  E. Levin,et al.  Nicotine–Haloperidol Interactions and Cognitive Performance in Schizophrenics , 1996, Neuropsychopharmacology.

[204]  I. McGregor,et al.  Adolescent Rats Find Repeated Δ9-THC Less Aversive Than Adult Rats but Display Greater Residual Cognitive Deficits and Changes in Hippocampal Protein Expression Following Exposure , 2008, Neuropsychopharmacology.

[205]  J. N. P. Rawlins,et al.  The effects of hippocampal lesions upon spatial and non-spatial tests of working memory , 1986, Behavioural Brain Research.

[206]  P. Barberger‐Gateau,et al.  The neuroprotective effects of caffeine , 2007, Neurology.

[207]  M. Ramírez,et al.  Effects of maternal separation on hypothalamic–pituitary–adrenal responses, cognition and vulnerability to stress in adult female rats , 2008, Neuroscience.

[208]  J. Feldon,et al.  Enhanced recognition memory following glycine transporter 1 deletion in forebrain neurons. , 2007, Behavioral neuroscience.

[209]  Mark Weiser,et al.  Higher Rates of Cigarette Smoking in Male Adolescents Before the Onset of Schizophrenia: A Historical-Prospective Cohort Study , 2004 .

[210]  E. Levin,et al.  Acute and Chronic Nicotinic Interactions with Dopamine Systems and Working Memory Performance a , 1995, Annals of the New York Academy of Sciences.

[211]  J. Waddington,et al.  Sexually dimorphic changes in the exploratory and habituation profiles of heterozygous neuregulin-1 knockout mice , 2006, Neuroreport.

[212]  Anne W. Schmidt,et al.  Clozapine increases dopamine release in prefrontal cortex by 5-HT1A receptor activation. , 1997, European journal of pharmacology.

[213]  R. Greene Circuit analysis of NMDAR hypofunction in the hippocampus, in vitro, and psychosis of schizophrenia † , 2001, Hippocampus.

[214]  S. Snyder,et al.  Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. , 1976, Science.

[215]  M. Sarter,et al.  Trans-synaptic stimulation of cortical acetylcholine and enhancement of attentional functions: a rational approach for the development of cognition enhancers , 1997, Behavioural Brain Research.

[216]  G. Griebel,et al.  SSR180711, a Novel Selective α7 Nicotinic Receptor Partial Agonist: (1) Binding and Functional Profile , 2007, Neuropsychopharmacology.

[217]  Ben Grayson,et al.  Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats. , 2010, The international journal of neuropsychopharmacology.

[218]  John B. Mitchell,et al.  The medial frontal cortex and temporal memory: tests using spontaneous exploratory behaviour in the rat , 1998, Behavioural Brain Research.

[219]  J. McGinty,et al.  Loss of Object Recognition Memory Produced by Extended Access to Methamphetamine Self-Administration is Reversed by Positive Allosteric Modulation of Metabotropic Glutamate Receptor 5 , 2011, Neuropsychopharmacology.

[220]  A. Sleight,et al.  Impact of regional 5-HT depletion on the cognitive enhancing effects of a typical 5-ht6 receptor antagonist, Ro 04-6790, in the Novel Object Discrimination task , 2008, Psychopharmacology.

[221]  R. Clark,et al.  Escalating dose, multiple binge methamphetamine regimen does not impair recognition memory in rats , 2007, Synapse.

[222]  M. Achaval,et al.  Early enriched housing results in partial recovery of memory deficits in female, but not in male, rats after neonatal hypoxia–ischemia , 2008, Brain Research.

[223]  P. Celada,et al.  In vivo actions of aripiprazole on serotonergic and dopaminergic systems in rodent brain , 2007, Psychopharmacology.

[224]  M. Morelli,et al.  Acute perinatal asphyxia impairs non-spatial memory and alters motor coordination in adult male rats , 2008, Experimental Brain Research.

[225]  Robert W. Buchanan,et al.  An open-labeled trial of adjunctive donepezil for cognitive impairments in patients with schizophrenia , 2003, Schizophrenia Research.

[226]  F. Berna,et al.  Functional Mechanisms of Episodic Memory Impairment in Schizophrenia , 2007, Canadian journal of psychiatry. Revue canadienne de psychiatrie.

[227]  E. Johnstone,et al.  Precursors and prodromata of schizophrenia: findings from the Edinburgh High Risk Study and their literature context , 2006, Psychological Medicine.

[228]  I. Grant,et al.  Neurocognitive Effects of Methamphetamine: A Critical Review and Meta-analysis , 2007, Neuropsychology Review.

[229]  E. Vizi,et al.  5-HT6/7 Receptor Antagonists Facilitate Dopamine Release in the Cochlea via a GABAergic Disinhibitory Mechanism , 2008, Neurochemical Research.

[230]  Fang Ji-qian Haplotype Transmission Disequilibrium Test Based on Haplotype Reconstruction , 2007 .

[231]  D. Souza,et al.  Caffeine prevents disruption of memory consolidation in the inhibitory avoidance and novel object recognition tasks by scopolamine in adult mice , 2010, Behavioural Brain Research.

[232]  M. Quirk,et al.  Selective alpha7 nicotinic receptor activation by AZD0328 enhances cortical dopamine release and improves learning and attentional processes. , 2009, Biochemical pharmacology.

[233]  M. Hasselmo,et al.  NMDA-dependent modulation of CA1 local circuit inhibition , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[234]  J. Feldon,et al.  Epidemiology-driven neurodevelopmental animal models of schizophrenia , 2010, Progress in Neurobiology.

[235]  L. Saksida,et al.  Object memory and perception in the medial temporal lobe: an alternative approach , 2005, Current Opinion in Neurobiology.

[236]  H. Akil,et al.  The 5-HT7 receptor: Role in novel object discrimination and relation to novelty-seeking behavior , 2007, Neuroscience.

[237]  D. Weinberger,et al.  Postpubertal Emergence of Hyperresponsiveness to Stress and to Amphetamine after Neonatal Excitotoxic Hippocampal Damage: A Potential Animal Model of Schizophrenia , 1993, Neuropsychopharmacology.

[238]  A. Simon,et al.  Opposing effects of AMPA and 5-HT1A receptor blockade on passive avoidance and object recognition performance: Correlation with AMPA receptor subunit expression in rat hippocampus , 2006, Neuropharmacology.

[239]  Peter B. Jones,et al.  Substance use in a population-based clinic sample of people with first-episode psychosis , 2007, British Journal of Psychiatry.

[240]  C. Robert Cloninger,et al.  Further investigation of a chromosome 15 locus in schizophrenia: analysis of affected sibpairs from the NIMH Genetics Initiative. , 1998, American journal of medical genetics.

[241]  T. Bussey,et al.  Glutamate Receptors in Perirhinal Cortex Mediate Encoding, Retrieval, and Consolidation of Object Recognition Memory , 2005, The Journal of Neuroscience.

[242]  P. Pauwels,et al.  E-6801, a 5-HT6 receptor agonist, improves recognition memory by combined modulation of cholinergic and glutamatergic neurotransmission in the rat , 2011, Psychopharmacology.

[243]  J. Delacour,et al.  A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data , 1988, Behavioural Brain Research.

[244]  Graham V. Williams,et al.  Inverted-U dopamine D1 receptor actions on prefrontal neurons engaged in working memory , 2007, Nature Neuroscience.

[245]  Carol A. Tamminga,et al.  Subanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia , 1995, Neuropsychopharmacology.

[246]  L. Saksida,et al.  Paradoxical Facilitation of Object Recognition Memory after Infusion of Scopolamine into Perirhinal Cortex: Implications for Cholinergic System Function , 2006, The Journal of Neuroscience.

[247]  Richie Poulton,et al.  Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study , 2002, BMJ : British Medical Journal.

[248]  B. Pouzet,et al.  Beneficial effects of galantamine on performance in the object recognition task in Swiss mice: Deficits induced by scopolamine and by prolonging the retention interval , 2006, Pharmacology Biochemistry and Behavior.

[249]  J. Krystal,et al.  Toward a rational pharmacotherapy of comorbid substance abuse in schizophrenic patients , 1999, Schizophrenia Research.

[250]  N. Schröder,et al.  Memantine reduces oxidative damage and enhances long-term recognition memory in aged rats , 2007, Neuroscience.

[251]  T. Rubino,et al.  Long-lasting recovery of psychotic-like symptoms in isolation-reared rats after chronic but not acute treatment with the cannabinoid antagonist AM251. , 2012, The international journal of neuropsychopharmacology.

[252]  S. O'dell,et al.  Methamphetamine Influences on Recognition Memory: Comparison of Escalating and Single-Day Dosing Regimens , 2008, Neuropsychopharmacology.

[253]  J. Krystal,et al.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. , 1994, Archives of general psychiatry.

[254]  J. Gold,et al.  Initial phase 2 trial of a nicotinic agonist in schizophrenia. , 2008, The American journal of psychiatry.

[255]  L. Squire,et al.  The visual paired-comparison task as a measure of declarative memory. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[256]  N. Alpert,et al.  Impaired recruitment of the hippocampus during conscious recollection in schizophrenia , 1998, Nature Neuroscience.

[257]  M. Bös,et al.  Influence of the 5-HT6 receptor on acetylcholine release in the cortex: pharmacological characterization of 4-(2-bromo-6-pyrrolidin-1-ylpyridine-4-sulfonyl)phenylamine, a potent and selective 5-HT6 receptor antagonist. , 2003, Journal of medicinal chemistry.

[258]  J. Neill,et al.  Asenapine improves phencyclidine-induced object recognition deficits in the rat: evidence for engagement of a dopamine D1 receptor mechanism , 2011, Psychopharmacology.

[259]  K. Mcfarland,et al.  AC-260584, an orally bioavailable M1 muscarinic receptor allosteric agonist, improves cognitive performance in an animal model , 2010, Neuropharmacology.

[260]  D. Goff,et al.  A six-month, placebo-controlled trial of d-cycloserine co-administered with conventional antipsychotics in schizophrenia patients , 2005, Psychopharmacology.

[261]  R. Freedman,et al.  Evidence in postmortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia , 1995, Biological Psychiatry.

[262]  J. Bachevalier,et al.  A comparison of children's performance on two recognition memory tasks: delayed nonmatch-to-sample versus visual paired-comparison. , 1993, Developmental psychobiology.

[263]  M. Garcia-Alloza,et al.  Lack of localization of 5‐HT6 receptors on cholinergic neurons: implication of multiple neurotransmitter systems in 5‐HT6 receptor‐mediated acetylcholine release , 2006, The European journal of neuroscience.

[264]  T. Rubino,et al.  Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia. , 2009, The international journal of neuropsychopharmacology.

[265]  Young-Chul Chung,et al.  Effect of donepezil added to atypical antipsychotics on cognition in patients with schizophrenia: An open-label trial , 2009, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[266]  N. Pitsikas,et al.  The 5-HT1A receptor antagonist WAY 100635 improves rats performance in different models of amnesia evaluated by the object recognition task , 2003, Brain Research.

[267]  D. Weinberger,et al.  Neonatal Damage of the Ventral Hippocampus Impairs Working Memory in the Rat , 2002, Neuropsychopharmacology.

[268]  J. Hagan,et al.  Isolation rearing induces recognition memory deficits accompanied by cytoskeletal alterations in rat hippocampus , 2006, The European journal of neuroscience.

[269]  P. Seeman,et al.  Dopamine D4 receptors elevated in schizophrenia , 1993, Nature.

[270]  V. Gallo,et al.  cAMP-dependent Protein Kinase Induces cAMP-response Element-binding Protein Phosphorylation via an Intracellular Calcium Release/ERK-dependent Pathway in Striatal Neurons* , 2001, The Journal of Biological Chemistry.

[271]  A. de Mendonça,et al.  Does caffeine intake protect from Alzheimer's disease? , 2002, European journal of neurology.

[272]  M Mishkin,et al.  An analysis of short-term visual memory in the monkey. , 1975, Journal of experimental psychology. Animal behavior processes.

[273]  K. Hashimoto,et al.  Immune Activation During Pregnancy in Mice Leads to Dopaminergic Hyperfunction and Cognitive Impairment in the Offspring: A Neurodevelopmental Animal Model of Schizophrenia , 2006, Biological Psychiatry.

[274]  B. Finlay,et al.  Translating developmental time across mammalian species , 2001, Neuroscience.

[275]  A. Young,et al.  PD168077, a D4 receptor agonist, reverses object recognition deficits in rats: potential role for D4 receptor mechanisms in improving cognitive dysfunction in schizophrenia , 2011, Journal of psychopharmacology.

[276]  J. Neill,et al.  Extrasynaptic GABAA receptor activation reverses recognition memory deficits in an animal model of schizophrenia , 2011, Psychopharmacology.

[277]  E X Albuquerque,et al.  Properties of neuronal nicotinic acetylcholine receptors: pharmacological characterization and modulation of synaptic function. , 1997, The Journal of pharmacology and experimental therapeutics.

[278]  J. Bizot,et al.  Intraseptal infusions of a low dose of AP5, a NMDA receptor antagonist, improves memory in an object recognition task in rats , 1998, Neuroscience Letters.

[279]  J. Aggleton,et al.  Spontaneous object recognition and object location memory in rats: the effects of lesions in the cingulate cortices, the medial prefrontal cortex, the cingulum bundle and the fornix , 1997, Experimental Brain Research.

[280]  J. Neill,et al.  Positive modulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors reverses sub-chronic PCP-induced deficits in the novel object recognition task in rats , 2010, Behavioural Brain Research.

[281]  J. Gardiner Recognition failures and free-recall failures: Implications for the relation between recall and recognition , 1988, Memory & Cognition.

[282]  G. Reynolds,et al.  Neonatal lipopolysaccharide induces pathological changes in parvalbumin immunoreactivity in the hippocampus of the rat , 2009, Behavioural Brain Research.

[283]  T. Bussey,et al.  Removal of cholinergic input to perirhinal cortex disrupts object recognition but not spatial working memory in the rat , 2005, The European journal of neuroscience.

[284]  E. Tulving How many memory systems are there , 1985 .

[285]  Michael F. Green,et al.  Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE Trial. , 2007, Archives of general psychiatry.

[286]  W. Riedel,et al.  Cholinergic drugs affect novel object recognition in rats: relation with hippocampal EEG? , 2007, European journal of pharmacology.

[287]  T. Ehmann,et al.  Donepezil in schizophrenia — is it helpful? An experimental design case study , 2001, Acta psychiatrica Scandinavica.

[288]  Rosemary A. Cowell,et al.  Double Dissociation between the Effects of Peri-Postrhinal Cortex and Hippocampal Lesions on Tests of Object Recognition and Spatial Memory: Heterogeneity of Function within the Temporal Lobe , 2004, The Journal of Neuroscience.

[289]  K. Hashimoto,et al.  d-Serine and a glycine transporter inhibitor improve MK-801-induced cognitive deficits in a novel object recognition test in rats , 2008, Behavioural Brain Research.

[290]  H. Prast,et al.  Nitric oxide as modulator of neuronal function , 2001, Progress in Neurobiology.

[291]  H. Praag,et al.  Caffeine attenuates scopolamine-induced memory impairment in humans , 2005, Psychopharmacology.

[292]  A. Sleight,et al.  5-HT6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation—an effect sensitive to NMDA receptor antagonism , 2004, Neuropharmacology.

[293]  Lawrence A. Rothblat,et al.  Short-term object recognition memory in the rat: nonmatching with trial-unique junk stimuli. , 1987 .

[294]  L. W. Cooke,et al.  Synthesis and SAR of tolylamine 5-HT6 antagonists. , 2009, Bioorganic & medicinal chemistry letters.

[295]  V. Marzo,et al.  The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders , 2003 .

[296]  Philip D. Harvey,et al.  Differential preservation of cognitive functions in geriatric patients with lifelong chronic schizophrenia: less impairment in reading compared with other skill areas , 2000, Biological Psychiatry.

[297]  R. Murray,et al.  Haplotype transmission disequilibrium and evidence for linkage of the CHRNA7 gene region to schizophrenia in Southern African Bantu families. , 2000, American journal of medical genetics.